CAD: ACC/AHA 2023 Chronic Coronary Disease Guideline Key Points: J Am Coll Cardiol. 2023 Aug, 82 (9) 956–960

These are the key points from this 2023 ACC/AHA guideline in managing chronic coronary disease.

• Patients with chronic coronary disease should receive care from a team of healthcare professionals (Team-based, patient-centered care)
• All patients with chronic coronary disease should be encouraged to make healthy lifestyle changes (nonpharmacologic therapies).
• Patients with chronic coronary disease who can exercise should be encouraged to participate in habitual physical activity.
• Sodium-glucose cotransporter two inhibitors and glucagon-like peptide-1 receptor agonists can be helpful for some patients with chronic coronary disease.
• Beta-blockers are no longer recommended for all patients with chronic coronary disease except in people who have had a heart attack in the past year, have a left ventricular ejection fraction of less than 50%, or have another condition that requires them to take beta-blockers.
• Statins are still the first-line therapy for lowering cholesterol in patients with chronic coronary disease. Consider PCSK9i, inclisiran, and bempedoic acid as alternative or additional therapies.
• Shorter durations of dual antiplatelet therapy are safe and effective in many patients with chronic coronary disease.
• There is no evidence that nonprescription or dietary supplements benefit patients with chronic coronary disease.
• Routine periodic anatomic or ischemic testing is not recommended for risk stratification or to guide therapeutic decision-making in patients with chronic coronary disease.
• E-cigarettes increase the likelihood of successful smoking cessation compared with nicotine replacement therapy, but they are not recommended as first-line therapy for smoking cessation.




Reference article: https://doi.org/10.1016/j.jacc.2023.06.006